Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H. Barouch, Ludo Lavreys, Kathryn E. Stephenson et al.|The Lancet|2018Cited by 342
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in AdultsGlenda Gray, Lubbe Wiesner, Linda‐Gail Bekker et al.|New England Journal of Medicine|2021Cited by 231
Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV)Khadija Khan, Rajhmun Madansein, Gila Lustig et al.|Clinical Infectious Diseases|2021Cited by 43
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda Gray, Mookho Malahleha, Kathryn Mngadi et al.|The Lancet Infectious Diseases|2024Cited by 40
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Helen Rees, Jinal N. Bhiman et al.|PLOS Global Public Health|2024Cited by 12